Actively Recruiting
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Led by M.D. Anderson Cancer Center · Updated on 2026-04-15
36
Participants Needed
1
Research Sites
222 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
L
Lantheus Medical Imaging
Collaborating Sponsor
AI-Summary
What this Trial Is About
To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer
CONDITIONS
Official Title
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- ECOG performance status of 2 or less (Karnofsky score 60% or higher)
- Able and willing to provide written informed consent
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma, hepatocellular carcinoma, or invasive lobular carcinoma of the breast
- Clinical or radiological suspicion of metastatic disease or confirmed metastasis with possible greater tumor burden
- At least one measurable lesion on standard imaging (CT, MRI, or FDG PET-CT) meeting size criteria
- Ability and willingness to undergo biopsy or clinical follow-up as standard of care to confirm PET-CT findings
- Either treatment naive or actively treated with suboptimal response and planned biopsy
- Estimated life expectancy of at least 3 months as determined by physician
You will not qualify if you...
- Pregnant or breastfeeding women
- History of allergic reactions to PSMA PET radiopharmaceuticals
- Psychiatric illness or social situations limiting study compliance
- Unable to lie flat or tolerate PET-CT scan
- Received chemotherapy, immunotherapy, or radiotherapy within 4 weeks prior to PYLARIFY injection
- Subjects with any medical condition or circumstance compromising safety or study compliance
- Patients with other types of pancreatic, hepatic, or breast cancers besides those specified
- Effect of androgen deprivation or related therapies on PYLARIFY PET is not established, consider carefully
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
Y
Yang Lu, MD, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here